We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Flow Cytometry Assay Speeds Diagnosis of Pediatric Tuberculosis

By LabMedica International staff writers
Posted on 14 Sep 2014
Epidemiologists working with samples obtained from groups of children in Tanzania, used a novel blood test to quickly diagnose victims of pediatric tuberculosis (TB).

The diagnosis of pediatric tuberculosis is complicated by nonspecific symptoms, difficult specimen collection, and the low number of organisms usually observed in biopsy specimens.

Investigators at the Swiss Tropical and Public Health Institute (Basel, Switzerland) and colleagues at Ludwigs-Maximilians-Universität (Munich, Germany) worked with samples collected from children with symptoms that suggested tuberculosis who had been prospectively recruited at the NIMR-Mbeya Medical Research Center in Mbeya (Tanzania), and the Ifakara Health Institute in Bagamoyo (Tanzania), between May 10, 2011, and September 4, 2012. More...
Sputum and peripheral blood mononuclear cells were obtained for Mycobacterium tuberculosis culture and for performance assessment of the novel TAM-TB blood test.

The TAM-TB assay is based on flow cytometry detection of loss of the CD27 surface marker usually expressed on CD4+ T-cells. This marker disappears after infection of these cells by M. tuberculosis. Results from this assay are available in about 24 hours as compared to results from culture, which require about 20 days.

Among 290 children screened in this study, the investigators selected a subgroup of 130 to ensure testing of at least 20 with culture-confirmed tuberculosis. Of this group of 130, 17 children were excluded because of inconclusive TAM-TB assay results. The TAM-TB assay enabled detection of 15 of 18 culture-confirmed cases (sensitivity 83.3%). Specificity was 96.8% in the 63 cases that were classified as not tuberculosis, with little effect from latent tuberculosis infection. The TAM-TB assay identified five additional patients with highly probable or probable tuberculosis, in whom M. tuberculosis was not isolated.

"This rapid and reliable test has the great potential to significantly improve the diagnosis of active tuberculosis in children," said contributing author Dr. Klaus Reither, TB CHILD Program Manager at the Swiss Tropical and Public Health Institute.

The study was published in the September 1, 2014, online edition of the journal Lancet Infectious Diseases.

Related Links:
Swiss Tropical and Public Health Institute
Ludwigs-Maximilians-Universität


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.